CD274 and neoplasm: In addition to targeted therapy, recent success with immunotherapies that block the immune inhibition of programmed death 1 (PD-1) protein or its ligand PD-L1 in different tumor types has brought major advances for the treatment of advanced NSCLC4–7, including squamous NSCLC.